PMGC
ELAB | NASDAQ
$1.66
+$0.08 (+5.06%)
At close: Nov 16, 2026, 4:00 PM ET
$1.56
-$0.10 (-6.05%)
After-hours:
Nov 16, 2026, 7:58 PM ET
+5.06%
(1D)No price chart data available for 1D timeframe.
Rating
33.8
+1.0 ptsFundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #686/1021 (Top 67%)
Key Statistics
Market Data
Market Cap $1.34M
1D Range
1.45 1.78
52W Range
1.45 5,164.80
Valuation (TTM)
PE 0
PB 0.11
EV/EBITDA 0.02
Valuation (NTM)
Forward PE N/A
Forward PEG -0.00
Price Target $0.00
Cash Flow
FCF Yield -156.0%
SBC Adj. FCF Yield -156.8%
SBC Impact -0.5%
Margins
Gross Margin 17.1%
Operating Margin -260.9%
FCF Margin -43.5%
Growth (CAGR)
Revenue 3Y | 5Y 61.1% |
37.6%
Dil EPS 3Y | 5Y 101.4% |
-49.5%
FCF 3Y | 5Y 40.2% |
-40.6%
Returns
ROA -10.0%
ROE -107.9%
ROIC -9.8%
Financial Health
Net Cash
$1.58M
Current Ratio 1.27
Interest Coverage -4.97
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering eng...
Sector Healthcare
Industry Biotechnology
Employees 33
IPO Date Nov 21, 2023
Website pmgcholdings.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove ELAB